Entrada Therapeutics Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $512.71 million
- Book Value:
- Revenue TTM:
- $43.43 million
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Entrada Therapeutics Inc had its IPO on 2021-10-29 under the ticker symbol TRDA.
The company operates in the Healthcare sector and Biotechnology industry. Entrada Therapeutics Inc has a staff strength of 131 employees.
Shares of Entrada Therapeutics Inc opened at $13.73 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $13.73 - $14.95, and closed at $14.7.
This is a 0% increase from the previous day's closing price.
A total volume of 35,878 shares were traded at the close of the day’s session.
In the last one week, shares of Entrada Therapeutics Inc have slipped by -4.61%.
Entrada Therapeutics Inc's Key Ratios
Entrada Therapeutics Inc has a market cap of $512.71 million, indicating a price to book ratio of 2.568 and a price to sales ratio of 0.
In the last 12-months Entrada Therapeutics Inc’s revenue was $43.43 million with a gross profit of $0 and an EBITDA of $-71281000. The EBITDA ratio measures Entrada Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Entrada Therapeutics Inc’s operating margin was -169.45% while its return on assets stood at -11.65% with a return of equity of -35.58%.
In Q2, Entrada Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Entrada Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-2.18 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Entrada Therapeutics Inc’s profitability.
Entrada Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -4.6529. Its price to sales ratio in the trailing 12-months stood at 0.
Entrada Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $493.98 million
- Total Liabilities
- $125.94 million
- Operating Cash Flow
- Capital Expenditure
- $1.52 million
- Dividend Payout Ratio
Entrada Therapeutics Inc ended 2023 with $493.98 million in total assets and $0 in total liabilities. Its intangible assets were valued at $493.98 million while shareholder equity stood at $206.91 million.
Entrada Therapeutics Inc ended 2023 with $0 in deferred long-term liabilities, $125.94 million in other current liabilities, 3000.00 in common stock, $-220887000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $376.79 million and cash and short-term investments were $376.79 million. The company’s total short-term debt was $7,409,000 while long-term debt stood at $0.
Entrada Therapeutics Inc’s total current assets stands at $390.20 million while long-term investments were $0 and short-term investments were $297.05 million. Its net receivables were $3.74 million compared to accounts payable of $2.42 million and inventory worth $0.
In 2023, Entrada Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $1.52 million.
Comparatively, Entrada Therapeutics Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Entrada Therapeutics Inc stock is currently trading at $14.7 per share. It touched a 52-week high of $24.38 and a 52-week low of $24.38. Analysts tracking the stock have a 12-month average target price of $21.5.
Its 50-day moving average was $15.96 and 200-day moving average was $14.59 The short ratio stood at 30.36 indicating a short percent outstanding of 0%.
Around 1496.2% of the company’s stock are held by insiders while 7496.9% are held by institutions.
Frequently Asked Questions About Entrada Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company’s lead therapeutic candidates, which include ENTR-601-44 and ENTR-601-45, which are in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1; ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy; and ENTR-701, which is in preclinical trail for the treatment of myotonic dystrophy type 1. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.